Bio-Rad Laboratories has unveiled Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8. This launch broadens the reach of Bio-Rad’s cutting-edge Droplet Digital™ PCR (ddPCR) technology, enabling precise assessment of critical quality attributes (CQAs) for AAV vector production.

AAV2 is the most prevalent serotype in clinical trials, and AAV8 plays a critical role in liver-targeted therapies. These kits complement existing solutions for AAV5 and AAV9, collectively addressing approximately 70% of the AAV gene therapy market. Researchers now have an expanded toolkit to accurately quantify capsid titer, genome titer, and full-to-empty capsid ratios for purified or crude lysate samples.

Key Features of the Vericheck ddPCR™ Empty-Full Capsid Kits:

• Support for AAV serotypes 2 and 8.
• Accurate absolute quantification using minimal sample volumes.
• Compatibility with Bio-Rad’s Droplet Digital PCR Systems.
• Validated for consistency across AAV production workflows.
• Adherence to regulatory guidelines for CQAs in gene therapy.

By streamlining the characterization of AAV vectors, Bio-Rad empowers researchers to advance gene therapies with confidence and precision.